2815 Eastlake Avenue East
161 articles with TapImmune Inc.
TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing
TapImmune Inc. (NASDAQ: TPIV), today announced the closing of the previously announced merger with privately-held Marker Therapeutics, Inc.
TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant
Mayo Clinic Receives $11 Million to Study TPIV110 in Combination with Trastuzumab (Herceptin®)
TapImmune Inc. today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming investor conferences. Mr. Hoang will present at the Cantor Global Healthcare Conference, to be held October 1-3, 2018
TapImmune Inc. will participate at two upcoming industry conferences.
TapImmune Inc. today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities.
TapImmune Inc. announced that its President and CEO, Peter L. Hoang, will present at the Jefferies 2018 Global Healthcare Conference.
TapImmune Inc. will participate in a panel discussion and give a company presentation at the 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum.
TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center
TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has expanded its recently formed Scientific Advisory Board (SAB) and will support the continued clinical development of the Company's transformative, non-genetically engineered, multi-antigen T cell therapy platform.
TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
Welcomes Renowned Thought Leaders Dr. Malcolm Brenner, Dr. Helen Heslop, and Dr. Cliona Rooney
TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
TapImmune Inc. (NASDAQ: TPIV) ("TapImmune") today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. ("Marker"), a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
TapImmune Inc. announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Disruptive Growth & Healthcare Conference, held May 8-9, 2018 at Reed Smith LLP in New York City.
TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research
Phase 1 Demonstration of Safety and Long-Lasting Immune Responses in Ovarian and Breast Cancer Conference Call and Live Audio Webcast Scheduled for Today at 9:00 AM ET to Discuss the Results
TapImmune Inc. announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the Sachs BioCapital USA Forum, held March 21st, 2018.
TapImmune Announces Enrollment of First Patient in Phase II Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense
The 280-patient trial, sponsored by Mayo Clinic, received $13.3M in grant funding from the DoD to evaluate the prevention of cancer recurrence in women with TNBC who have completed first-line surgery and radiotherapy/chemotherapy.
In this newly created role at TapImmune, Dr. Kenney will continue to manage the Company's ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates.
A public conference call and live audio webcast is scheduled for today at 4:30 p.m. ET.
The event will be webcast live via the Internet on: November 15, 2017 4:30 p.m. ET
TapImmune Completes Patient Enrollment Ahead of Schedule in Phase II Cancer Vaccine Study for Treating Triple-Negative Breast Cancer
The comprehensive four-arm study is designed to help determine the optimal vaccine dose and regimen to maximize the immune response generated against the vaccine's molecular target, FRa.
TapImmune announces a letter from the CEO.